Eureka Therapeutics possesses an ADCC assay platform that facilitates the selection of antibody drug candidates.
We provide ADCC assay services to determine antibody ADCC activity against specified target cell lines. The assay service includes optimization of E/T ratios and measurement of ADCC activity at a series of antibody concentrations. Tests with PBMC cells from multiple donors can be requested.
Upon request, Eureka Therapeutics can conduct polymorphic genotyping of the donors' blood for position 158 V/F variations.
*ADCC Assay of Herceptin against SKBR-3 cells performed at Eureka Therapeutics
Download our
ADCC Assay Service Description for more information.
Please contact us for more details.